Clinical Trials Logo

Propionibacterium Acnes clinical trials

View clinical trials related to Propionibacterium Acnes.

Filter by:
  • None
  • Page 1

NCT ID: NCT04021524 Completed - Clinical trials for Propionibacterium Acnes

BPO vs Hibiclens Soap for Surgical Preparation

Start date: September 10, 2018
Phase: Phase 4
Study type: Interventional

This is a randomized trial of benzoyl peroxide soap versus Hibiclens soap for surgical preparation. The objective is to determine whether benzoyl peroxide soap, commonly available in drug stores for over-the-counter acne treatment, is as or more effective than the standard surgical preoperative soap, Hibiclens soap (chlorhexidine gluconate), in reducing loads of Propionibacteria (Propi) on or under the skin of patients prior to shoulder arthroplasty (joint replacement).

NCT ID: NCT03057821 Completed - Clinical trials for Propionibacterium Acnes

Propionibacterium Acnes in Shoulder Arthroplasty

Start date: January 2017
Phase: N/A
Study type: Interventional

The investigator's plan to determine whether pre-operative skin preparation with hydrogen peroxide alters rates of P acnes culture positivity. They hypothesize that pre-operative skin preparation with hydrogen peroxide will reduce rates of P acnes culture positivity.

NCT ID: NCT00211523 Completed - Acne Vulgaris Clinical Trials

Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne

Start date: October 2000
Phase: Phase 2
Study type: Interventional

This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.

NCT ID: NCT00211497 Completed - Acne Vulgaris Clinical Trials

Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

Start date: January 2003
Phase: Phase 2
Study type: Interventional

This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with facial acne vulgaris.